AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on AAREYDRUGS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.40
- • RSI: 67
- • MACD: bullish
- • Price vs EMA21: above
- • 1-month return: +17.0%
- • 1-month vs NIFTY: +21.1% relative
Bull case
- • Debt/Equity: 0.40
- • RSI: 67
- • MACD: bullish
- • Price vs EMA21: above
Bear case
- • Revenue growth: -56.3% YoY
- • Profit growth: -25.0% YoY
- • Volatility: 51% annualized
- • Max drawdown (1y): 49%
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -56.3% YoY
- • Profit growth: -25.0% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.16). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.